Dermata Therapeutics Inc. has announced a one-for-10 reverse stock split of its common stock, effective August 1, 2025. The reverse split will consolidate every ten shares into one, with trading on a split-adjusted basis expected to commence on the Nasdaq Capital Market. The move will not alter the par value or authorized number of shares. Stockholders granted the board the discretion to implement the reverse split within a specified ratio range, with the board approving the final ratio. Fractional shares will be compensated with cash payments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.